Inhibition of human smooth muscle cell proliferation in culture by farnesyl pyrophosphate analogues, inhibitors of in vitro protein:farnesyl transferase

Biochemical Pharmacology

Volumn 57, Issue 4, 1999, Pages 365-373

  Cohen, Louis H ^a   Pieterman, Elsbet ^a   Van Leeuwen, Rick E W ^a   Du, Junrong ^a   Negre Aminou, Pascale ^a   Valentijn, A Rob P M ^a   Overhand, Mark ^a   Van Der Marel, Gijs A ^a   Van Boom, Jacques H ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

bFGF; DNA synthesis; PDGF; Protein:geranylgeranyl transferase 1; Ras; Signal transduction; Squalene synthase

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; FARNESENE DERIVATIVE; GERANYLTRANSFERASE; GROWTH FACTOR; MIDAZOLAM MALEATE; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SQUALENE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CELL DIVISION; CELL LINE; CELLS, CULTURED; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MUSCLE, SMOOTH; PLATELET-DERIVED GROWTH FACTOR; POLYISOPRENYL PHOSPHATES; RATS;

EID: 0032898892     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00322-0     Document Type: Article

References (32)

1. Ross R. The pathogenesis of atherosclerosis A perspective for the 1990's . Nature. 362:1993;801-806.
2. Schwartz S.M., de Blois D., O'Brien E.R. The intima. Soil for atherosclerosis and restenosis. Circ Res. 77:1995;445-465.
3. Oikawa S. Human arterial smooth muscle cell proliferation in diabetes. Diabetes. 45:1996;S114-S116.
4. McCully K.S. Homocysteine and vascular disease. Nat Med. 2:1996;386-389.
5. Libby P., Schwartz D., Brogi E., Tanaka H., Clinton S.K. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation. 86:1992;47-52.
6. Mattsson E., Clowes A.W. Current concepts in restenosis following balloon angioplasty. Trends Cardiovas Med. 5:1995;200-204.
7. Lever A.F. Slow pressor mechanisms in hypertension a role for hypertrophy of resistance vessels? J Hypertens. 4:1986;515-524.
8. Mulvany M.J. Role of vascular structure in blood pressure development of the spontaneously hypertensive rat. J Hypertens. 4:1986;61-63.
9. Jackson C.L., Schwartz S.M. Pharmacology of smooth muscle cell replication. Hypertension. 20:1992;713-736.
10. Nègre-Aminou P., van Vliet A.K., Van Erck M., van Thiel G.C.F., van Leeuwen R.E.W., Cohen L.H. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors Comparison with other human cell types . Biochim Biophys Acta. 1345:1997;259-268.
11. Mulcahy L.S., Smith M.R., Stacey D.W. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature. 313:1985;241-243.
12. Olson M.F., Ashworth A., Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 269:1995;1270-1272.
13. Ras farnesyl-protein transferase by Cys-AAX tetrapeptides. Cell. 62:1990;81-88.
14. Yokoyama K., Goodwin G.W., Ghomashchi F., Glomset J.A., Gelb M.H. A protein geranylgeranyltransferase from bovine brain-Implications for protein prenylation specificity. Proc Natl Acad Sci USA. 88:1991;5302-5306.
15. Moores S.L., Shaber M.D., Mosser S.D., Rands E., O'Hara M.B., Garsky V.M., Marshall M.S., Pompliano D.L., Gibbs J.B. Sequence dependence of protein isoprenylation. J Biol Chem. 266:1991;14603-14610.
16. James G.L., Goldstein J.L., Brown M.S., Rawson T.E., Somers T.C., McDowell R.S., Crowley C.W., Lucas B.K., Levinson A.D., Marters J.C. Jr. Benzodiazepine peptidomimetics potent inhibitors of Ras farnesylation in animal cells . Science. 260:1993;1937-1942.
17. Gibbs J.B., Oliff A., Kohl N.E. Farnesyltransferase inhibitors-Ras research yields a potential cancer therapeutic. Cell. 77:1994;175-178.
18. James G.L. Goldstein, JL and Brown MS, Polylysine and CVIM sequences of k-Rasb dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem. 270:1995;6221-6226.
19. Cohen L.H., Valentijn A.R.P.M., Roodenburg L., van Leeuwen R.E.W., Huisman R.H., Lutz R.J., van der Marel G.A., van Boom J.H. Different analogues of farnesyl pyrophosphate inhibit squalene synthase and protein:farnesyltransferase to different extents. Biochem Pharmacol. 49:1995;839-845.
20. Downward J., De Gunzburg J., Riehl R., Weinberg R.A. p21ras-induced responsiveness of phosphatidylinositol turnover to bradykinin is a receptor number effect. Proc Natl Acad Sci USA. 85:1988;5774-5778.
21. Valentijn ARPM, van der Marel GA, Cohen LH and van Boom JH, An expeditious synthesis of pyrophosphate analogues of farnesyl pyrophosphate using the phosphonylating agent methyl methylphosphonomorpholidate. Synlett 663-664, 1991.
22. Valentijn A.R.P.M., van den Berg O., van der Marel G.A., Cohen L.H., van Boom J.H. A novel approach towards the synthesis of pyrophosphate analogues of farnesyl pyrophosphate. Recueil des Travaux Chimiques des Pays-Bas. 113:1994;563-566.
23. Valentijn A.R.P.M., de Haan R., Hagens S., de Kant E., van der Marel G.A., Cohen L.H., van Boom J.H. Synthesis of a potential enzyme-specific inhibitor of squalene synthase. Recueil des Travaux Chimiques des Pays-Bas. 115:1995;332-336.
24. Valentijn A.R.P.M., van den Berg O., van der Marel G.A., Cohen L.H., van Boom J.H. Synthesis of pyrophosphonic acid analogues of farnesyl pyrophosphate. Tetrahedron. 51:1995;2099-2108.
25. Valentijn A.R.P.M., Broxterman H.J.G., van der Marel G.A., Cohen L.H., van Boom J.H. Synthesis of 1,6-anhydro-2,3-di-O-farnesyl-5-O-([{phosphonomethyl}phosphinyl]methyl)-α- D-galactofuranose A zaragozic acid-presqualene pyrophosphate hybrid . J Carbohyd Chem. 14:1995;737-749.
26. Overhand M., Pieterman E., Cohen L.H., Valentijn A.R.P.M., van der Marel G.A., van Boom J.H. Synthesis of triphosphonate analogues of farnesyl pyrophosphate, inhibitors of squalene synthase and protein:farnesyl transferase. Bioorg Med Chem Lett. 7:1997;2435-2440.
27. Kinsella B.T., Erdman R.A., Maltese W.A. Posttranslational modification of Ha-ras p21 by farnesyl versus geranylgeranyl isoprenoids is determined by the COOH-terminal amino acid. Proc Natl Acad Sci USA. 88:1991;8934-8938.
28. Biller S.A., Sofia M.J., Delange B., Forster C., Gordon E.M., Harrity T., Rich L.C., Ciosek C.P. The 1st potent inhibitor of squalene synthase-a profound contribution of an ether oxygen to inhibitor enzyme interaction. J Am Chem Soc. 113:1991;8522-8524.
29. Ciosek C.P., Magnin D.R., Harrity T.W., Logan J.V.H., Dickson J.K., Gordon E.M., Hamilton K.A., Jolibois K.G., Kunselman L.K., Lawrence R.M., Mookhtiar K.A., Rich L.C., Slusarchyk D.A., Sulsky R.B., Biller S.A. Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol-lowering agents in vivo. J Biol Chem. 268:1993;24832-24837.
30. Kolodyazhnyi OI, Yakovlev VI, Grishkun EV, Kovalenko AB and Kukhar VP, Carbon-phosphorous analogues of natural prenyl pyrophosphates. Dopov Akad Nauk Ukr RSR Ser B: Geol Khim Biol Nauki, 51-53, 1987 Chem Abstr 108: 38140g, 1988.
31. Kolodyazhnyi OI, Yakovlev VI, Grishkun EV, Kovalenko AB and Kukhar VP, Carbon-phosphorous analogues of natural prenyl pyrophosphates. Dopov Akad Nauk Ukr RSR Ser B: Geol Khim Biol Nauki, 51-53, 1987 Chem Abstr 108: 38140g, 1988.
32. Dickson J.K., Biller S.A., Magnin D.R., Petrillo E.W., Hillyer J.W., Hsieh D.C., Lan S.J., Rinehart J.K., Gregg R.E., Harrity T.W., Jolibois K.G., Kalinowski S.S., Kunselman L.K., Mookhtiar K.A., Ciosek C.P. Orally active squalene synthase inhibitors Bis((acyloxy)alkyl)prodrugs of the alpha-phosphonosulfonic acid moiety . J Med Chem. 39:1996;661-664.